Christopher Johnson
Radiation Oncology · Baltimore, MDNPI 1619330289
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,080 of the $7,044 with a category attached, or 86.3%. AstraZeneca accounts for 86.3% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $6,266, more than ten times the $257 reported in 2021.
Across 12 payments — averaging $587.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Novocure Inc.$309
- Progenics Pharmaceuticals, Inc.$180
- Palette Life Sciences, Inc.$163
- Teleflex LLC$143
- Janssen Scientific Affairs, LLC$111
- plus $58 from 1 others
What the payments were for
- Consulting fees$6,08086%
- Food & beverage$96414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $6,080 |
| Novocure Inc. | 3 | $309 |
| Progenics Pharmaceuticals, Inc. | 2 | $180 |
| Palette Life Sciences, Inc. | 1 | $163 |
| Teleflex LLC | 2 | $143 |
| Janssen Scientific Affairs, LLC | 1 | $111 |
| Bioprotect Medical, Inc. | 2 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$6,080
- Optune$146
- OPTUNE LUA (NOVOTTF-200T)$126
- Tremfya$111
How this compares
$7,044 in reported general payments places this provider in the 85th percentile of 108 radiation oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 18 | $265 |
| Tamsulosin Hcl | 28 | $255 |
| Pantoprazole Sodium | 42 | $210 |
| Dexamethasone | 17 | $201 |
| Memantine Hcl | 14 | $165 |
| Lorazepam | 11 | $16 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Baltimore
- Sahaja AcharyaBaltimore$200K
- Arpit ChhabraBaltimore$97K
- Lawrence KleinbergBaltimore$34K
- Danny SongBaltimore$32K
- Jason MolitorisBaltimore$26K
- Kristin RedmondBaltimore$17K
- Avani RaoBaltimore$10K
- Amanda WalkerBaltimore$9K
- Russell HalesBaltimore$7K
- Harry QuonBaltimore$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.